Martin v. BioXcel Therapeutics, Inc. et al

  1. July 12, 2024

    AI Drugmaker BioXcel Beats Investor Fraud Suit, For Now

    A Connecticut federal judge has tossed a proposed securities fraud class action against BioXcel Therapeutics Inc., saying that while shareholders sufficiently alleged the AI-driven drugmaker made misleading statements concerning a dementia drug study's compliance issues, they failed to adequately plead the company intended to deceive or defraud investors.

  2. June 24, 2024

    Judge Mulls BioXcel's Duty To Tell Investors Of FDA Troubles

    A Connecticut federal judge wondered Monday if executives at the artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. had an opportunity to correct problems that government regulators identified with a key clinical trial and, if so, whether their statements on the subject to investors could be considered false or misleading.

  3. February 09, 2024

    AI Drugmaker Wants Investor Suit Over Botched Trial Tossed

    Artificial intelligence-based drugmaker BioXcel Therapeutics Inc. is urging a Connecticut federal court to drop a suit accusing it of failing to disclose stumbles that allegedly affected the integrity of a dementia drug study, arguing it took necessary steps to inform the public and the government that the trial had been jeopardized.

  4. October 06, 2023

    2 Firms To Rep BioXcel Investors In Suit Against AI Drugmaker

    Levi & Korsinsky LLP and Grant & Eisenhofer PA will co-lead a proposed shareholder class action in Connecticut alleging AI-based drugmaker BioXcel Therapeutics Inc. hurt investors after announcing plans to investigate results of a study of one of its drugs.

  5. September 07, 2023

    Attys Vie To Lead Investor Suit Against AI-Based Drugmaker

    Seven legal teams have filed bids to represent a proposed class of investors in artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. in a suit alleging that it hurt investors after announcing plans to investigate results of a study of one of its drugs.

  6. July 10, 2023

    AI-Based Pharma Co. Faces Investor Suit Over Study Woes

    Artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. has been hit with a proposed shareholder class action accusing the company of failing to disclose stumbles that allegedly affected the integrity of a study of a drug for agitated seniors with dementia.